Abiogen acquires EffRx to fortify bone disease portfolio
Pharmaceutical Technology
MAY 30, 2023
Alkindi is one of EffRx’s three marketed drugs. The company’s last deal included an exclusive license agreement with the Cardiff, UK-headquartered specialty pharmaceuticals company Diurnal group for the commercialisation of Efmody (hydrocortisone) in Switzerland.
Let's personalize your content